Comparison of patients with newly diagnosed (ND) acute myeloid leukemia (AML) treated with venetoclax and hypomethylating agents vs other therapies by TP53 and IDH1/2 mutation: Results from the AML Real World Evidence (ARC) Initiative Meeting Abstract
| Authors: | Wolach, O.; Garcia, J. S.; Desai, P.; Vachhani, P.; Zeidner, J. F.; Abedin, S.; Sweet, K.; Lai, C.; Moshe, Y.; Pollyea, D. A.; Xavier, M.; Nachmias, B.; Zuckerman, T.; Lee, S.; Chen, E. C.; Bathini, S.; Edwards, W.; Bui, C. N.; Cheng, W. H.; Miller, C.; Guerin, A.; Maitland, J.; Ma, E.; Montez, M.; Grunspan, M.; Goldberg, A. D. |
| Abstract Title: | Comparison of patients with newly diagnosed (ND) acute myeloid leukemia (AML) treated with venetoclax and hypomethylating agents vs other therapies by TP53 and IDH1/2 mutation: Results from the AML Real World Evidence (ARC) Initiative |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 11026 |
| End Page: | 11028 |
| Language: | English |
| ACCESSION: | WOS:000893230304018 |
| DOI: | 10.1182/blood-2022-159615 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
